Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exparel for pain control after one-level posterior spinal fusion
NCT03745040Phase 4Suspended
- Sponsor
- Allina Health
- Start
- Jan 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bupivacaine in postoperative pain (2 arms), sponsored by Allina Health. Primary endpoint: Visual Analog Pain Scores at 2.5 days. Started Jan 2019; status: suspended.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03745040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745040.